NovaBay Pharmaceuticals Company Profile (NYSEMKT:NBY)

About NovaBay Pharmaceuticals (NYSEMKT:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:NBY
  • CUSIP: N/A
  • Web:
  • Market Cap: $66.59 million
  • Outstanding Shares: 15,309,000
Average Prices:
  • 50 Day Moving Avg: $4.46
  • 200 Day Moving Avg: $3.80
  • 52 Week Range: $2.25 - $5.09
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -48.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $15.34 million
  • Price / Sales: 4.34
  • Book Value: $0.21 per share
  • Price / Book: 20.71
  • EBITDA: ($9,470,000.00)
  • Net Margins: -42.16%
  • Return on Equity: -184.30%
  • Return on Assets: -56.33%
  • Average Volume: 14,948 shs.
  • Beta: 0.22
  • Short Ratio: 0.3

Frequently Asked Questions for NovaBay Pharmaceuticals (NYSEMKT:NBY)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals shares reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) released its quarterly earnings data on Thursday, May, 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.56. The firm earned $1.70 million during the quarter, compared to the consensus estimate of $1.84 million. NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%. View NovaBay Pharmaceuticals' Earnings History.

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 12-month price objectives for NovaBay Pharmaceuticals' stock. Their predictions range from $5.50 to $10.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $7.17 in the next year. View Analyst Ratings for NovaBay Pharmaceuticals.

Who are some of NovaBay Pharmaceuticals' key competitors?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:

  • Mark M. Sieczkarek, Interim Chairman of the Board, President, Chief Executive Officer
  • John McGovern, Chief Financial Officer, Treasurer
  • Justin M. Hall Esq., Senior Vice President, General Counsel
  • Xinzhou Li, Director
  • Xiaoyan Liu, Director
  • Yonghao Ma Ph.D., Director
  • Mijia Wu, Director
  • Todd E. Zavodnick, Director

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $4.35.

MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEMKT NBY)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NovaBay Pharmaceuticals (NYSEMKT:NBY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $7.17
Consensus Price Target History for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Price Target History for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Analysts' Ratings History for NovaBay Pharmaceuticals (NYSEMKT:NBY)
DateFirmActionRatingPrice TargetDetails
6/5/2017Roth CapitalReiterated RatingBuy$5.50View Rating Details
3/27/2017Maxim GroupReiterated RatingHoldView Rating Details
3/27/2017LaidlawInitiated CoverageBuy$10.00View Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 10/17/2015 forward)


Earnings History for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Earnings by Quarter for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Earnings History by Quarter for NovaBay Pharmaceuticals (NYSEMKT NBY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2016Q116($0.68)($1.24)$1.84 million$1.70 millionViewListenView Earnings Details
3/3/2016Q415($1.36)($1.26)$1.43 million$1.60 millionViewN/AView Earnings Details
11/19/2015Q315($0.07)($0.07)$1.06 million$1.20 millionViewListenView Earnings Details
8/13/2015Q215($0.07)($0.07)$610.00 millionViewListenView Earnings Details
5/14/2015Q1($0.06)($0.09)ViewN/AView Earnings Details
3/26/2015Q414($0.07)($0.09)ViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.08)ViewN/AView Earnings Details
7/31/2014($0.09)($0.06)ViewN/AView Earnings Details
5/1/2014Q114($0.11)($0.08)ViewN/AView Earnings Details
11/12/2013Q3($0.10)ViewN/AView Earnings Details
5/2/2013Q113($0.07)($0.11)$1.18 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.09)($0.08)$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Current Year EPS Consensus Estimate: $-0.47 EPS
Next Year EPS Consensus Estimate: $-0.09 EPS


Dividend History for NovaBay Pharmaceuticals (NYSEMKT:NBY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Insider Trades by Quarter for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Insider Trades by Quarter for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Ramin NajafiCEOBuy12,000$0.47$5,640.00View SEC Filing  
3/3/2015Pharma (Singapore) Pte PioneerMajor ShareholderBuy2,590,000$0.60$1,554,000.00View SEC Filing  
3/3/2015Ramin NajafiChairmanBuy166,666$0.60$99,999.60View SEC Filing  
12/12/2014Ramin NajafiChairmanBuy50,000$0.65$32,500.00View SEC Filing  
12/12/2014Thomas J PaulsonCFOBuy10,000$0.68$6,800.00View SEC Filing  
12/11/2014Ramin NajafiChairmanBuy20,000$0.60$12,000.00View SEC Filing  
12/9/2014Thomas J PaulsonCFOBuy10,000$0.67$6,700.00View SEC Filing  
12/5/2014Ramin NajafiChairmanBuy25,000$0.65$16,250.00View SEC Filing  
12/2/2014Ramin NajafiChairmanBuy18,000$0.71$12,780.00View SEC Filing  
12/2/2014Tony D.S. WicksDirectorSell20,000$0.70$14,000.00View SEC Filing  
6/4/2014Mark M SieczkarekDirectorBuy4,800$0.89$4,272.00View SEC Filing  
5/19/2014Mark M SieczkarekDirectorBuy25,000$0.88$22,000.00View SEC Filing  
5/13/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy65,065$0.99$64,414.35View SEC Filing  
5/12/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy116,107$0.99$114,945.93View SEC Filing  
5/9/2014Pioneer Pharma Holdings ChinaMajor ShareholderBuy318,828$0.99$315,639.72View SEC Filing  
12/2/2013Pioneer Pharma Holdings ChinaMajor ShareholderBuy5,000,000$1.14$5,700,000.00View SEC Filing  
12/11/2012Xinzhou LiInsiderBuy120,000$1.20$144,000.00View SEC Filing  
12/6/2012Ramin NajafiChairmanBuy20,000$1.24$24,800.00View SEC Filing  
12/6/2012Thomas J PaulsonCFOBuy10,000$1.24$12,400.00View SEC Filing  
10/31/2012Area Pioneer Pharma Co. NaquMajor ShareholderBuy1,200,000$1.25$1,500,000.00View SEC Filing  
9/13/2012Xinzhou LiMajor ShareholderBuy800,000$1.25$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NovaBay Pharmaceuticals (NYSEMKT:NBY)
Latest Headlines for NovaBay Pharmaceuticals (NYSEMKT:NBY)
DateHeadline logoETFs with exposure to NovaBay Pharmaceuticals, Inc. : September 19, 2017 - September 20 at 6:45 AM logoEye Surgeon Says Keep Eyelids Healthy with Avenova from NovaBay - September 19 at 1:36 AM logoNovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 - September 19 at 1:36 AM logoNovaBay (NBY) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 14 at 8:07 AM logoNovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference - September 6 at 6:41 AM logoNovaBay's Avenova Offers Key Benefits in Glaucoma Care - August 15 at 2:44 AM logoInvestor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - August 11 at 6:49 AM logoNovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results - August 11 at 6:49 AM logoNovaBay Pharmaceuticals to Hold 2017 Second Quarter Conference Call on August 10, 2017 - August 4 at 6:11 AM logoNovaBay Pharmaceuticals Announces CFO Transition - July 11 at 3:07 AM logoNovaBay's Avenova Highlighted in National Dry Eye Awareness Month - July 11 at 3:07 AM logoUPDATE: NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - July 11 at 3:07 AM logoNOVABAY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report - March 23 at 7:17 PM logoQ4 2016 NovaBay Pharmaceuticals Inc Earnings Release - After Market Close - March 23 at 8:45 AM logoNovaBay Pharma (NBY) to Present Feature, Benefits of intelli-Case at FDA Public Advisory Meeting - - March 11 at 1:05 AM logoNovaBay Pharmaceuticals To Present Information On intelli-Case Contact Disinfectant To FDA - March 10 at 8:04 PM logoNovaBay Pharmaceuticals to Present Features and Benefits of the intelli-Case at FDA Public Advisory Meeting - March 9 at 8:30 AM logoNovaBay Pharmaceuticals to Present at 29 - Business Wire (press release) - March 7 at 6:35 PM logoCoverage initiated on NovaBay Pharma by Rodman & Renshaw - February 6 at 9:38 AM logoNovaBay Pharmaceuticals Announces Preliminary Sales for the Fourth Quarter of 2016 - January 9 at 7:28 PM logo6:53 am NovaBay Pharma sees Q4 revs above single est - January 9 at 7:28 PM logoNOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and - December 19 at 9:48 AM logo3 Pharmaceuticals Stocks to Buy Now - - December 11 at 5:54 PM logoNovaBay to Present at LD Micro Main Event - Business Wire (press release) - December 1 at 9:22 AM logoNovaBay Pharma (NBY) Notes Positive OCLI Publication on Avenova - - November 30 at 11:56 PM



NovaBay Pharmaceuticals (NBY) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.